Hepatocellular Carcinoma (HCC) Clinical Trials in Beijing, Beijing Municipality
6 recruitingBeijing, Beijing Municipality, China
Showing 1–6 of 6 trials
Recruiting
Phase 1Phase 2
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
Advanced or Unresectable Hepatocellular Carcinoma (HCC)
Huahui Health30 enrolled21 locationsNCT07547553
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb198 enrolled59 locationsNCT07291076
Recruiting
Not Applicable
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
Breast CancerColorectal, CancerPancreatic Cancer+11 more
Peking University First Hospital200 enrolled1 locationNCT07557225
Recruiting
Phase 2
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
Hepatocellular Carcinoma (HCC)
Abbisko Therapeutics Co, Ltd141 enrolled51 locationsNCT07327034
Recruiting
Phase 2
NWRD06 DNA Plasmid for HCC After Curative Resection.
Hepatocellular Carcinoma (HCC)
Newish Technology (Beijing) Co., Ltd.30 enrolled6 locationsNCT07324304
Recruiting
Phase 1
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma (HCC)
AbbVie20 enrolled11 locationsNCT06487559